ArticlePloS one2011
Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Mucosal CCL28 Chemokine Improves Protection against Genital Herpes through Mobilization of Antiviral Effector Memory CCR10+CD44+ CD62L-CD8+ T Cells and Memory CCR10+B220+CD27+ B Cells into the Infected Vaginal Mucosa.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Article
- Generation of IL-3-Secreting CD4ImmunoHorizons · 2019Article
- Evaluation of the fusion inhibitor P3 peptide as a potential microbicide to prevent HIV transmission in women.PloS one · 2018Article
- Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Article
- The Cholestanol-Conjugated Sulfated Oligosaccharide PG545 Disrupts the Lipid Envelope of Herpes Simplex Virus Particles.Antimicrobial agents and chemotherapy · 2016Article
- The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment.Journal of virology · 2015Article
- Multipurpose prevention technologies: the future of HIV and STI protection.Trends in microbiology · 2015Review
- Dynasore disrupts trafficking of herpes simplex virus proteins.Journal of virology · 2015Article
- Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease.eLife · 2015Article
- Article
- In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition.Antiviral research · 2014Article
- Genital herpes simplex virus type 2 infection in humanized HIV-transgenic mice triggers HIV shedding and is associated with greater neurological disease.The Journal of infectious diseases · 2014Article
- Cultivated vaginal microbiomes alter HIV-1 infection and antiretroviral efficacy in colonized epithelial multilayer cultures.PloS one · 2014Article
- Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety.Antimicrobial agents and chemotherapy · 2014Article
- Article
- Standard operating procedures for maintaining cleanliness in a novel compact facility for breeding SPF mice.Journal of the American Association for Laboratory Animal Science : JAALAS · 2013Article
- Short communication: expression of transporters and metabolizing enzymes in the female lower genital tract: implications for microbicide research.AIDS research and human retroviruses · 2013Article
- HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppression.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2013Article
- Griffithsin protects mice from genital herpes by preventing cell-to-cell spread.Journal of virology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundDespite significant protection in preclinical studies, cellulose sulfate (CS) failed to protect women against HIV-1/2 and was associated with a trend toward increased HIV-1 acquisition in one of the clinical trials. These results highlight the need for preclinical tests more predictive of clinical outcomes. The objective of this study was to test coded vaginal gels, including CS, in murine models of safety and efficacy to determine the models' utility for evaluating future products.
methodsFour coded formulations, including 6% CS, 2% PRO 2000 and two placebo gels, were administered intravaginally to medroxyprogesterone-treated mice and their ability to prevent genital herpes (efficacy) or to alter the susceptibility to low dose HSV challenge (safety) was determined. Nonoyxnol-9 served as a positive toxicity control.
resultsCS and PRO 2000 significantly protected mice from genital herpes following infection with a laboratory or clinical isolate of HSV-2 introduced in buffer (p<0.001). However, protection was reduced when virus was introduced in seminal plasma. Moreover, mice were significantly more susceptible to infection with low doses of HSV-2 when challenged 12 h after the 7th daily dose of CS or nonoxynol-9 (p<0.05). The increased susceptibility was associated with alterations in epithelial architecture.
conclusionsCS prevented genital herpes when present at the time of viral challenge, but increased the rate of infection when gel was applied daily for 7 days with a vaginal wash prior to viral inoculation. The findings presumably reflect altered epithelial architecture, which may have contributed to the trend towards increased HIV observed clinically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.